Diagnosis and management of autoimmune myasthenia gravis.
Earlier diagnosis and the availability of effective treatments have reduced the burden of high mortality and severe disability previously associated with myasthenia gravis (MG). Consequently, the prognosis of MG is now much improved. However, despite extensive knowledge of MG and its aetiology, diagnosing the disease remains problematic and can be delayed because of its nonspecific and fluctuating symptoms, and the management of MG is associated with considerable limitations. Current treatments based on immunomodulation are associated with adverse effects arising from prolonged immune suppression. There is a need for improved awareness among primary caregivers about this relatively rare, but treatable, disease.
Department of Neurosciences, University of Padova, Padova, Italy and IRCSS S. Camillo, Venice, Italy. corrado.angelini@unipd.it
Corrado
C
Angelini
D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008959:Models, Neurological; D009157:Myasthenia Gravis / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology / Q000601:surgery; D013934:Thymectomy
D002800:Cholinesterase Inhibitors; D007166:Immunosuppressive Agents